Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy
dc.contributor.buuauthor | Özkan, Hasan Atilla | |
dc.contributor.buuauthor | Hakyemez, Bahattin | |
dc.contributor.buuauthor | Özkalemkaş, Fahir | |
dc.contributor.buuauthor | Ali, Rıdvan | |
dc.contributor.buuauthor | Özkocaman, Vildan | |
dc.contributor.buuauthor | Özçelik, Tülay | |
dc.contributor.buuauthor | Taşkapılıoğlu, Özlem | |
dc.contributor.buuauthor | Altundal, Yıldız | |
dc.contributor.buuauthor | Tunalı, Ayfer | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Radyoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Nöroloji Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-3425-0740 | tr_TR |
dc.contributor.researcherid | X-3647-2018 | tr_TR |
dc.contributor.researcherid | AAI-2318-2021 | tr_TR |
dc.contributor.researcherid | AAG-8495-2021 | tr_TR |
dc.contributor.researcherid | AAH-1854-2021 | tr_TR |
dc.contributor.scopusid | 9250698600 | tr_TR |
dc.contributor.scopusid | 6602527239 | tr_TR |
dc.contributor.scopusid | 6601912387 | tr_TR |
dc.contributor.scopusid | 7201813027 | tr_TR |
dc.contributor.scopusid | 6603145040 | tr_TR |
dc.contributor.scopusid | 7005424333 | tr_TR |
dc.contributor.scopusid | 23037226400 | tr_TR |
dc.contributor.scopusid | 15080726300 | tr_TR |
dc.contributor.scopusid | 6602797853 | tr_TR |
dc.date.accessioned | 2021-11-18T06:39:00Z | |
dc.date.available | 2021-11-18T06:39:00Z | |
dc.date.issued | 2006 | |
dc.description.abstract | Introduction Reversible posterior leukoencephalopathy syndrome (RPLS) is a recently described clinical and radiological entity comprising headache, seizures, altered level of consciousness and visual disturbances in association with transient posterior cerebral white-matter abnormalities. Method We report a young woman with Burkitt's lymphoma who developed RPLS after combined chemotherapy administered during the tumor lysis syndrome. Results The symptoms in this patient fitted well with those of RPLS; they included abrupt alterations in mental status, seizures, headache, visual changes and characteristic neuroradiological findings. She was given further combination chemotherapy without any neurological complications, at which time she had already recovered from both RPLS and tumor lysis syndrome. Conclusion Although many etiological factors have been reported in the development of RPLS, the underlying mechanism is not yet well understood. With prompt and appropriate management, RPLS is usually reversible, and chemotherapy can be continued after complete recovery from RPLS. We suggest that tumor lysis syndrome should be considered as a contributory factor to the development of RPLS in patients for whom treatment with combined chemotherapy for hematological malignancies is planned. | en_US |
dc.identifier.citation | Özkan, A. vd. (2006). ''Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy''. Neuroradiology, 48(12), 887-892. | en_US |
dc.identifier.endpage | 892 | tr_TR |
dc.identifier.issn | 0028-3940 | |
dc.identifier.issn | 1432-1920 | |
dc.identifier.issue | 12 | tr_TR |
dc.identifier.pubmed | 16983525 | tr_TR |
dc.identifier.scopus | 2-s2.0-33751536932 | tr_TR |
dc.identifier.startpage | 887 | tr_TR |
dc.identifier.uri | https://doi.org/10.1007/s00234-006-0142-8 | |
dc.identifier.uri | https://link.springer.com/article/10.1007/s00234-006-0142-8 | |
dc.identifier.uri | http://hdl.handle.net/11452/22706 | |
dc.identifier.volume | 48 | tr_TR |
dc.identifier.wos | 000242365500004 | tr_TR |
dc.indexed.pubmed | Pubmed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer | en_US |
dc.relation.journal | Neuroradiology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Neurosciences & neurology | en_US |
dc.subject | Radiology, nuclear medicine & medical imaging | en_US |
dc.subject | Tumor lysis syndrome | en_US |
dc.subject | Reversible posterior leukoencephalopathy syndrome | en_US |
dc.subject | MRI | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Leukemia | en_US |
dc.subject | Lymphoma | en_US |
dc.subject | Vasospasm | en_US |
dc.subject | Patient | en_US |
dc.subject | Combination chemotherapy | en_US |
dc.subject | Encephalopathy syndrome | en_US |
dc.subject.emtree | Vincristine | en_US |
dc.subject.emtree | Phenytoin | en_US |
dc.subject.emtree | Methotrexate | en_US |
dc.subject.emtree | Doxorubicin | en_US |
dc.subject.emtree | Dexamethasone | en_US |
dc.subject.emtree | Cytarabine | en_US |
dc.subject.emtree | Cyclophosphamide | en_US |
dc.subject.emtree | Corticosteroid | en_US |
dc.subject.emtree | Allopurinol | en_US |
dc.subject.emtree | Weight reduction | en_US |
dc.subject.emtree | Vomiting | en_US |
dc.subject.emtree | Tumor lysis syndrome | en_US |
dc.subject.emtree | Tonic clonic seizure | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.emtree | Reversible posterior leukoencephalopathy syndrome | en_US |
dc.subject.emtree | Rehydration | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Pathogenesis | en_US |
dc.subject.emtree | Nausea; nuclear magnetic resonance imaging | en_US |
dc.subject.emtree | Leukoencephalopathy | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Hospital admission | en_US |
dc.subject.emtree | Headache | en_US |
dc.subject.emtree | Grand mal seizure | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Computer assisted tomography | en_US |
dc.subject.emtree | Coma | en_US |
dc.subject.emtree | Case report | en_US |
dc.subject.emtree | Cancer combination chemotherapy | en_US |
dc.subject.emtree | Burkitt iymphoma | en_US |
dc.subject.emtree | Blurred vision | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Abdominal pain | en_US |
dc.subject.mesh | Tumor lysis syndrome | en_US |
dc.subject.mesh | Syndrome | en_US |
dc.subject.mesh | Seizures | en_US |
dc.subject.mesh | Magnetic resonance imaging | en_US |
dc.subject.mesh | Hypertensive encephalopathy | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Headache | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fatal outcome | en_US |
dc.subject.mesh | Coma | en_US |
dc.subject.mesh | Burkitt lymphoma | en_US |
dc.subject.mesh | Blindness, cortical | en_US |
dc.subject.mesh | Antineoplastic combined chemotherapy protocols | en_US |
dc.subject.scopus | Posterior Reversible Encephalopathy Syndrome; Eclampsia; Hypertension Encephalopathy | en_US |
dc.subject.wos | Clinical neurology | en_US |
dc.subject.wos | Neuroimaging | en_US |
dc.subject.wos | Radiology, nuclear medicine & medical imaging | en_US |
dc.title | Tumor lysis syndrome as a contributory factor to the development of reversible posterior leukoencephalopathy | en_US |
dc.type | Article | |
dc.wos.quartile | Q2 (Neuroimaging) | en_US |
dc.wos.quartile | Q3 | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: